The upregulation of miR-155 may also promote autoimmune inflammation through the targeted inhibition of cytokine signaling 1 (SOCS1) and SH2 domain-containing inositol-5-phosphatase 1 (SHIP1) (65). Here, INPP5D is linked to inflammatory response.